137 related articles for article (PubMed ID: 35711123)
1. Mapping the FACT-G to EQ-5D-3L utility index in cancer with the Chinese values set.
He Z; Liang W; Xu W; Huang W; Wang X; Huang K; Yang L
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1103-1116. PubMed ID: 35711123
[TBL] [Abstract][Full Text] [Related]
2. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
3. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
4. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
5. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
Jiang L; Zhou H; Yang Q; Luo X; Huang D
Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
[TBL] [Abstract][Full Text] [Related]
6. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
Huang D; Peng J; Chen N; Yang Q; Jiang L
Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
[TBL] [Abstract][Full Text] [Related]
7. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
8. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
9. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
Su J; Liu T; Li S; Zhao Y; Kuang Y
J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
[No Abstract] [Full Text] [Related]
10. Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
Young TA; Mukuria C; Rowen D; Brazier JE; Longworth L
Med Decis Making; 2015 Oct; 35(7):912-26. PubMed ID: 25997920
[TBL] [Abstract][Full Text] [Related]
11. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
12. Obtaining EQ-5D-3L utility index from the health status scale of traditional Chinese medicine (TCM-HSS) based on a mapping study.
Wang L; Lu Y; Dai Z; Shi P; Xu J; Chang F; Lu Y
Health Qual Life Outcomes; 2022 Dec; 20(1):164. PubMed ID: 36522665
[TBL] [Abstract][Full Text] [Related]
13. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
14. Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients.
Shafie AA; Chhabra IK; Wong JHY; Mohammed NS
Eur J Health Econ; 2021 Jul; 22(5):735-747. PubMed ID: 33860379
[TBL] [Abstract][Full Text] [Related]
15. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
16. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
Diels J; Hamberg P; Ford D; Price PW; Spencer M; Dass RN
Qual Life Res; 2015 Mar; 24(3):591-8. PubMed ID: 25326871
[TBL] [Abstract][Full Text] [Related]
17. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
[TBL] [Abstract][Full Text] [Related]
18. Can EQ-5D-3L utility values of low back pain patients be validly predicted by the Oswestry Disability Index for use in cost-effectiveness analyses?
Pellekooren S; Ben ÂJ; Bosmans JE; Ostelo RWJG; van Tulder MW; Maas ET; Huygen FJPM; Oosterhuis T; Apeldoorn AT; van Hooff ML; van Dongen JM
Qual Life Res; 2022 Jul; 31(7):2153-2165. PubMed ID: 35040002
[TBL] [Abstract][Full Text] [Related]
19. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
20. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
